Ultime notizie per TScan Therapeutics (NASDAQ:TCRX) Azioni

TSCAN THERAPEUTICS INC

THL Credit, Inc. 6.75% Notes due 2021

TScan Therapeutics

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

TScan Therapeutics Inc

RBC Capital analyst Kenneth Lee reiterates Kayne Anderson BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBDC#NYSE">KBDC</a>) with a Outperform and maintains $17 price target.

News

Price Target

Reiteration

Analyst Ratings

KBDC

RBC Capital Reiterates Outperform on Kayne Anderson BDC, Maintains $17 Price Target

RBC Capital analyst Ben Hendrix reiterates GoHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOCO#NASDAQ">GOCO</a>) with a Sector Perform and maintains $18 price target.

GOCO

RBC Capital Reiterates Sector Perform on GoHealth, Maintains $18 Price Target

- For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever better levels of stabilization achieved by treatment with acoramidis, a near-complete (≥90%) TTR stabilizer, lead to ever better clinical outcomes
- ATTRibute-CM is the only study to demonstrate a direct association between a prompt, sustained increase in serum TTR and survival in patients with ATTR-CM
- The open-label extension data for all ATTRibute-CM participants at Month 42 showed that rapid, sustained TTR stabilization from acoramidis demonstrated statistically significant reductions in ACM and CVH (including urgent outpatient treatment for heart failure exacerbations)
- In the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date in both ATTRv-CM and ATTRwt-CM patients:
- In as few as 3 months, the time to first event (ACM or CVH) durably separated relative&nbsp;to placebo - A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 - A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30
- Acoramidis is approved as Attruby&#x2122; by the U.S. FDA and is approved as BEYONTTRA&#xAE; by the European Commission, the Japanese Pharmaceuticals and Medical Devices Agency, and the UK Medicines and Healthcare Products Regulatory Agency
PALO ALTO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) ("BridgeBio" or the "Company"),&nbsp;a new type of biopharmaceutical company focused on genetic diseases, published data showing that an early, sustained increase in serum transthyretin (TTR) levels predicted improved survival in ATTRibute-CM, its Phase 3 trial of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). These findings were published in Journal of the American College of Cardiology (JACC) in the Special Focus Issue: Amyloid. Acoramidis is a selective, small molecule, orally administered, near-complete (≥90%) TTR stabilizer. These findings further support the thesis that ever better increases in serum TTR lead to ever better clinical outcomes and that early elevations in serum TTR are an important prognostic marker to inform treatment selection.

BBIO

Bridgebio Pharma Publishes Data Showing Sustained Increase In Serum TTR Levels Predicted Improved Survival In ATTRibute-CM, Phase 3 Trial Of ATTR-CM

<a href="https://www.dell.com/en-us/dt/events/delltechnologiesworld/2025/index.htm?msockid=21c662101c496b42343370ae1de86aaa#tab0=0&amp;accordion0" title="https://www.dell.com/en-us/dt/events/delltechnologiesworld/2025/index.htm?msockid=21c662101c496b42343370ae1de86aaa#tab0=0&amp;accordion0">https://www.dell.com/en-us/dt/events/delltechnologiesworld/2025/index.htm?msockid=21c662101c496b42343370ae1de86aaa#tab0=0&amp;accordion0</a>

DELL

NVDA

QCOM

Dell Technologies Says New PowerEdge Servers Can Be Customized With Up To 256 Nvidia Blackwell Ultra GPUs Per Dell IR7000 Rack; Plans To Support Nvidia Vera CPU; Plans To Support Nvidia Vera Rubin Platform With New Dell PowerEdge XE Server; Introduces Dell Pro Max Plus Laptop With Qualcomm AI 100 PC Inference Card

Dell Technologies Unveils Next Generation Enterprise AI Solutions With Nvidia; Introduces Air-Cooled Dell PowerEdge XE9780, XE9785 Servers & Liquid-Cooled Dell PowerEdge XE9780l, XE9785l Servers; New PowerEdge Servers Support Up To 192 Nvidia Blackwell Ultra GPUs With Direct To Chip Liquid Cooling

WIIM

Novo Nordisk shares are trading higher, rebounding after falling last week on a CEO departure announcement.

Morgan Stanley analyst Bob Huang maintains WR Berkley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) with a Equal-Weight and raises the price target from $63 to $75.

Morgan Stanley Maintains Equal-Weight on WR Berkley, Raises Price Target to $75

DOGZ

Dogness shares are trading higher after the company announced it entered into a share acquisition agreement to acquire a 19.5% equity interest in DITC

UnitedHealth shares are trading higher, rebounding following recent weakness.

Morgan Stanley analyst Bob Huang maintains Voya Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOYA#NYSE">VOYA</a>) with a Overweight and raises the price target from $70 to $86.

VOYA

Morgan Stanley Maintains Overweight on Voya Financial, Raises Price Target to $86

Morgan Stanley analyst Adam Jonas maintains Visteon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VC#NASDAQ">VC</a>) with a Equal-Weight and lowers the price target from $95 to $90.

Morgan Stanley Maintains Equal-Weight on Visteon, Lowers Price Target to $90

Somnigroup International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGI#NYSE">SGI</a>) has outperformed the market over the past 10 years by 5.2% on an annualized basis producing an average annual return of 16.11%. Currently, Somnigroup International has a market capitalization of $13.69 billion. 
Buying $1000 In SGI: If an investor had bought $1000 of SGI stock 10 years ago, it would be worth $4,451.86 today based on a price of $65.63 for SGI at the time of writing.
<h3>Somnigroup International's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747672213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Somnigroup International Stock In The Last 10 Years

Morgan Stanley analyst Nigel Dally maintains Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) with a Equal-Weight and raises the price target from $76 to $83.

Morgan Stanley Maintains Equal-Weight on Unum Gr, Raises Price Target to $83

Morgan Stanley analyst Bob Huang maintains TWFG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWFG#NASDAQ">TWFG</a>) with a Equal-Weight and raises the price target from $29 to $34.

TWFG

Morgan Stanley Maintains Equal-Weight on TWFG, Raises Price Target to $34

Live On CNBC, Bill Baruch Announces Bought Edward Lifesciences

YPF Sociedad Anonima shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and raised its price target from $44 to $48.

Morgan Stanley analyst Michael Phillips maintains Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) with a Equal-Weight and raises the price target from $245 to $269.

Morgan Stanley Maintains Equal-Weight on Travelers Companies, Raises Price Target to $269

SANM

Sanmina shares are trading lower after the company announced it acquired a data center infrastructure manufacturing business for $3 billion.

Wall Street's reaction to <a href="https://www.benzinga.com/news/econ-s/25/05/45479078/moodys-downgrades-us-credit-rating-over-debt-deficit-concerns">Moody's downgrade of U.S. debt </a>is turning into a tale of two titans. On one end, you have Ray Dalio — founder of Bridgewater Associates — warning that the downgrade grossly understates the true risk of owning U.S. debt.
On the other hand, there&#8217;s Tom Lee of Fundstrat. Lee brushed the downgrade off as a "non-event" and told investors to go shopping for stocks.
Moody's cut the U.S. credit rating from Aaa to Aa1, following in the footsteps of S&amp;P in 2011 and Fitch in 2023. With this move, the U.S. officially loses its AAA status across the board. 
But is it a flashing red signal or just another headline?
Read Also: <a href="https://www.benzinga.com/hedge-funds/25/05/45447966/ray-dalios-bridgewater-dumps-spy-trims-nvidia-meta-alphabet-bearish-vibes">Ray Dalio&#8217;s Bridgewater Dumps SPY, Trims Nvidia, Meta, Alphabet — Bearish Vibes?</a>
<h2 class="wp-block-heading">Ray Dalio: The Real Threat Isn&#8217;t Default, It Is&#8230;</h2>
Dalio didn't mince words. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Re the U.S. debt downgrade, you should know that credit ratings understate credit risks because they only rate the risk of the government not paying its debt. They don&#39;t include the greater risk that the countries in debt will print money to pay their debts thus causing holders…
&mdash; Ray Dalio (@RayDalio) <a href="https://twitter.com/RayDalio/status/1924452875108839862?ref_src=twsrc%5Etfw">May 19, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
He argued the real threat isn't default, but dilution — central banks printing money to meet obligations. 
"For those who care about the value of their money," he posted on X, "the risks for U.S. government debt are greater than the rating agencies are conveying." Translation? The downgrade misses the bigger picture: currency debasement.
<h2 class="wp-block-heading">Tom Lee: Downgrade = Largely &#8216;Non-Event&#8217;</h2>
Tom Lee, meanwhile, is telling clients to stay calm and keep buying. Like those before, he says this downgrade is unlikely to trigger panic. History might just be on his side — after S&amp;P's downgrade in 2011 and Fitch's in 2023, the S&amp;P 500 plunged roughly 10% in the short term but rallied over 35% within a year in both cases.
So what now? If Dalio's right, long-term bondholders could face slow bleed-through inflation, not default. But if Lee's playbook holds, a short-term dip could be just the setup bulls need.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/05/45491935/history-says-sp-500-could-fall-10-after-rating-downgrade-but-rally-35-after">S&amp;P 500 History Suggests 10% Drop After Downgrade — Followed By 35% Rally</a></li>
</ul>
Image: Shutterstock

Macro Economic Events

Hedge Funds

Economics

Dalio Sees Danger, Tom Lee Sees Dip-Buy: Who's Right About The US Credit Downgrade?

Morgan Stanley analyst Bob Huang maintains Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) with a Overweight and raises the price target from $320 to $330.

Morgan Stanley Maintains Overweight on Progressive, Raises Price Target to $330

Press Releases

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Financing

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dividends

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

Earnings

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Health Care

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Comments

TScan Therapeutics

Notizie

Ultime notizie per TScan Therapeutics (NASDAQ:TCRX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO